Literature DB >> 1362057

Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4.

P Seeman1.   

Abstract

Dopamine (DA) D2, D3, and D4 receptors are targets for antipsychotic drugs. The recent cloning, deoxyribonucleic acid sequencing, and brain location of these receptors provide new insight on the DA hypothesis of schizophrenia, particularly for the basis of antipsychotic therapy of schizophrenia. In schizophrenia brain tissue, D2 receptors are elevated and have lost the link to D1 receptors. Brain positron-emission tomography studies of patients may also reveal elevated D2, depending on the method used. Hallucinations and positive symptoms are blocked when about 70% of the D2 receptors are occupied by neuroleptic drugs. An analysis of the literature indicates that therapeutic concentrations of antipsychotic drugs (in the patient's cerebrospinal fluid or plasma water) act primarily at D2 receptors, with the exception of clozapine, which acts at D4 receptors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1362057

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  69 in total

Review 1.  Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.

Authors:  E Stip
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

2.  Schizophrenia: more dopamine, more D2 receptors.

Authors:  P Seeman; S Kapur
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

Review 3.  Advances in the pharmacological treatment of pathological gambling.

Authors:  Jon E Grant; Suck Won Kim; Marc N Potenza
Journal:  J Gambl Stud       Date:  2003

Review 4.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

5.  Relationship of orofacial movements to behavioural repertoire as assessed topographically over the course of 6-month haloperidol treatment followed by 4-month withdrawal.

Authors:  Ian E J De Souza; Niamh M Dawson; Jeremiah J Clifford; John L Waddington; Gloria E Meredith
Journal:  Psychopharmacology (Berl)       Date:  2003-06-27       Impact factor: 4.530

Review 6.  Understanding antipsychotic "atypicality": a clinical and pharmacological moving target.

Authors:  Gary Remington
Journal:  J Psychiatry Neurosci       Date:  2003-07       Impact factor: 6.186

7.  The differential contribution of dopamine D(1) and D (2) receptors to mu-opioidergic immunomodulation.

Authors:  M A Cheido; G V Idova
Journal:  Neurosci Behav Physiol       Date:  2007-09

8.  DARPP-32 and NCS-1 expression is not altered in brains of rats treated with typical or atypical antipsychotics.

Authors:  Bruno R Souza; Bernardo S Motta; Daniela V F Rosa; Karen C L Torres; Adalberto A Castro; Clarissa M Comim; André M Sampaio; Fabrício F Lima; Andreas Jeromin; João Quevedo; Marco A Romano-Silva
Journal:  Neurochem Res       Date:  2007-08-31       Impact factor: 3.996

9.  D1 and D2 dopamine receptor antagonists reverse prepulse inhibition deficits in an animal model of schizophrenia.

Authors:  D C Hoffman; H Donovan
Journal:  Psychopharmacology (Berl)       Date:  1994-08       Impact factor: 4.530

10.  The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers.

Authors:  Ahmed A Othman; George Haig; Hana Florian; Charles Locke; Lev Gertsik; Sandeep Dutta
Journal:  Br J Clin Pharmacol       Date:  2014-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.